Atai Life Sciences N.V. (NASDAQ:ATAI) traded with a subtraction of -$0.03 to $1.57 on Thursday, a downside of -2.19 percent. An average of 490,772 shares of common stock have been traded in the last five days. There was a fall of -$0.0201 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 600,193 shares traded, while the 50-day average volume stands at 1,076,301.
ATAI stock has decreased by -24.03% in the last month. The company shares reached their 1-month lowest point of $1.5200 on 08/24/23. With the stock rallying to its 52-week high on 01/04/23, shares of the company touched a low of $1.14 and a high of $4.96 in 52 weeks. It has reached a new high 2 times so far this year and lost -41.17% or -$1.0901 in price. In spite of this, the price is down -68.45% from the 52-week high.
Valuation Metrics
Atai Life Sciences N.V. (ATAIstock’s beta is 0.84. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 871.65, the price-to-book (PB) ratio at 1.15.
Financial Health
The quick ratio of Atai Life Sciences N.V. for the three months ended June 29 was 13.50, and the current ratio was 13.50, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.07 and a total debt to equity ratio of 0.07 for the quarter ending June 29. Atai Life Sciences N.V.’s EBITDA margin for the year ending June 29 is -61915.02%. Its gross profit as reported stood at $145.02 million compared to revenue of $0.23 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Atai Life Sciences N.V.’s return on assets was -49.10%.
Earnings Surprise
For the three-month period that ended June 29, Atai Life Sciences N.V. had $14.87 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$33.04 million in the quarter, while revenues of -$33.14 million were shrunk -10.84%. The analyst consensus anticipated Atai Life Sciences N.V.’s latest quarter earnings to come in at -$0.21 per share, but it turned out to be -$0.21, a 0.00% surprise. For the quarter, EBITDA amounted to -$31.78 million. Shareholders own equity worth $166.01 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Atai Life Sciences N.V. (ATAI) price momentum. RSI 9-day as of the close on 23 August was 29.01%, suggesting the stock is oversold, with historical volatility in this time frame at 40.64%.
As of today, ATAI’s price is $1.6020 -1.26% or -$0.0201 from its 5-day moving average. ATAI is currently trading -23.04% lower than its 20-day SMA and -13.27% lower than its 100-day SMA. However, the stock’s current price level is -13.74% below the SMA50 and -47.84% below the SMA200.
The stochastic %K and %D were 16.04% and 16.36%, respectively, and the average true range (ATR) was 0.0941. With the 14-day stochastic at 13.86% and the average true range at 0.1036, the RSI (14) stands at 34.00%. The stock has reached -0.0156 on the 9-day MACD Oscillator while the 14-day reading was at -0.0565.
Analyst Ratings
Loop Capital launched coverage on Atai Life Sciences N.V. (NASDAQ: ATAI) in its analyst report released on November 01, 2022. The firm assigned the stock a Buy rating. The consensus rating for Atai Life Sciences N.V. (ATAI) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ATAI, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 10 others rate it as a “buy”.
What is ATAI’s price target for the next 12 months?
Analysts predict a range of price targets between $5.10 and $21.00, with a median target of $11.00. Taking a look at these predictions, the average price target given by analysts for Atai Life Sciences N.V. (ATAI) stock is $11.90.
